

Special Issue

Approaches to Navigating Multi-Drug Resistance in Gram-Negative Pathogens

Message from the Guest Editors

Acinetobacter baumannii is a ubiquitous Gram-negative bacterium and human colonizer. The organism has emerged as a problematic nosocomial pathogen due to its resilience within the hospital environment and innate ability to evade commonly used antibiotic therapy. This Special Issue welcomes various submission types, such as perspectives, reviews, case reports, brief reports, and original research papers that discuss antibiotic treatment for *A. baumannii* infections, with a special focus on multidrug resistance.

Keywords: multidrug-resistant pathogens; pharmacokinetics; pharmacodynamics; antibacterial; *Acinetobacter baumannii*, difficult to treat pathogens; carbapenem-resistant *Acinetobacter baumannii*

Guest Editors

Dr. Jacinda C. Abdul-Mutakabbir

1. Department of Pharmacy Practice, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA

2. Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, USA

Prof. Dr. Victor Nizet

Department of Pediatrics, UC San Diego, La Jolla, CA 92093, USA

Deadline for manuscript submissions

closed (31 July 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/110997

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)